2022
PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.
Shu F, Punekar S, Velcheti V, Sanmamed M, Wang J. PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy. Clinical Cancer Research 2022, 28: 3182-3184. PMID: 35648093, DOI: 10.1158/1078-0432.ccr-22-0541.Peer-Reviewed Original Research
2020
Expanding the Role of Immunotherapy to Limited-Stage SCLC
Punekar S, Shum E. Expanding the Role of Immunotherapy to Limited-Stage SCLC. Journal Of Thoracic Oncology 2020, 15: 1806-1808. PMID: 33246593, DOI: 10.1016/j.jtho.2020.09.021.Peer-Reviewed Original Research